Abstract

A NOVEL UPDATE ON ANTI-PLATELET AGENTS

Rohit S, Balasubramanian P* and Sambathkumar R

ABSTRACT

Anti-platelet drugs play a serious role in the therapy of patients having thrombotic events. These drugs are the linchpin in the therapy of cardiovascular disease. They remain active in preventing aberrant platelet activation in patho-physiological conditions like myocardial infarction, ischemia and stroke. At present, there are different agents that are approved and available for medical use and mentioned as per guidelines for the treatment and prevention of ischemic actions in the setting of acute coronary syndrome and percutaneus coronary intervention: (1) cycloxigenase-1 inhibitor: aspirin. (2) Adenosine diphosphate or P2Y12 receptor antagonists: clopidogrel, ticlopidine, prasugrel, and ticagrelor and (3) glycoprotein IIb/IIIa inhibitors: abciximab, eptifibatide and tirofiban. GPIs at present are available only in parenteral dosage form and therefore their usage only for the acute phase treatment of ACS patients. Those were being used as clinically distinct protective effects. So these were decrease the possibility of ischemic incidents without drastically increasing the rate of bleeding. Clinical trials are undergo other new anti-platelet agents also been introduced. Without doubt, the new anti- platelet agents are rising in number. Consequently, the effects of those anti-platelet agents in actual patients assure study. Expectantly, new selective anti-platelets with high anti thrombotic efficacy and low bleeding side effects are able to determine.

Keywords: anti-platelet agent, antagonist, thrombotic disease, new therapy.